News Headlines

  1. CellFiber And Tidewave Bio Enter Collaboration To Evaluate Scalable 3D Manufacturing For Next-Generation Solid Tumor Immunotherapy 8/5/2026

    CellFiber Co., Ltd. (“CellFiber”), a Tokyo-based biotechnology company built on its proprietary CellFiber® cell encapsulation platform, and Tidewave Bio (“Tidewave”), a Los Angeles-based biotechnology company developing a universal, off-the-shelf immunotherapy platform for solid tumors, today announced a collaboration to evaluate CellFiber’s closed, automated 3D cell culture platform in support of the scalable manufacturing of Tidewave’s next-generation cell immunotherapy.

  2. Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services To Commercialization 8/5/2026

    Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA).

  3. Evexta Bio Announces Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate Rupitasertib In Combination With A Selective Estrogen Receptor Degrader In Advanced / Metastatic Breast Cancer 8/4/2026

    Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer.

  4. Myellama Therapeutics And Vaxcellbio Sign MOU 8/4/2026

    Myellama Therapeutics has signed a strategic memorandum of understanding with Korean biotechnology company Vaxcellbio to co-develop therapies for multiple myeloma and other indications using its next-generation trispecific engager technology, developed with the National Research Council Canada (NRC).

  5. Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, In Non-Small Cell Lung Cancer 8/4/2026

    Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has entered into a Clinical Trial Collaboration and Supply Agreement (“CTCSA”) with Eli Lilly & Company (“Lilly”), to evaluate the combination of Amplia’s investigational FAK inhibitor, narmafotinib, with Lilly’s investigational KRAS G12C inhibitor, olomorasib.

  6. Wacker Biotech And Eclipsebio Announce Strategic Collaboration To Advance RNA Medicine Development And Production 8/4/2026

    Wacker Biotech, a leading contract development and manufacturing organization (CDMO) wholly owned by Wacker Chemie AG, and Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced a strategic collaboration.

  7. SOPHiA GENETICS Enters Collaboration To Develop Companion Diagnostics For Precision Oncology Therapies 8/4/2026

    SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

  8. Niagen Bioscience Selects Global Drug Development Pioneer Evotec To Advance Preclinical Development For NB4168 8/3/2026

    Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.

  9. Ginkgo Bioworks And Acies Bio Partner To Expand Global Access To High-Performance Aspergillus Niger Strains For Protein Production 8/3/2026

    Ginkgo Bioworks and Acies Bio, a European biotechnology company specializing in microbial strain development, bioprocess development, scale-up, and manufacturing, today announced a partnership that will combine one of Ginkgo's most versatile microbial "factories" with Acies to support companies around the world.

  10. Genezen And The Raiden Science Foundation Announce Partnership For AAV9 Gene Replacement Therapy For UBA5 Clinical Trial 8/3/2026

    Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), and the Raiden Science Foundation (RSF), a parent-led rare disease organization, today announced a manufacturing partnership for an AAV Serotype 9 gene replacement therapy for UBA5 disorder.